Intestinal microbiota, microbiome, Colorectal cancer treatment, chemotoxicity, respons Intestinale microbiota, microbioom, colorectaal carcinoom behandeling, chemotoxiciteit, respons
Conditions
Interventions
An explorative prospective multicenter cohort study in the Maastricht University Medical Centre+, Catharina Hospital and Zuyderland Medical Centre will be performed in 66 patients. Before, during, and
Sponsors
AZM
Eligibility
Inclusion criteria
Inclusion criteria: • Patients diagnosed with metastatic and/or irresectable CRC who will be treated with oral capecitabine (with or without intravenous bevacizumab) or oral trifluridine/tipiracil (TAS-102). • Aged 18 years or older. • Written informed consent.
Exclusion criteria
Exclusion criteria: • Proven Microsatellite instability (MSI). • Has not received any prior systemic therapy for the treatment of CRC during the previous 4 weeks prior to start of the current line of capecitabine or TAS-102. • Patients treated with additional systemic treatments during planned treatment period. • Radiotherapy within past 2 weeks prior to start. • Therapeutic antibiotic use within past 3 months prior to start. • Renal function: calculated creatinine clearance (Cockroft-Guilt) < 30 ml/min. •Pregnant or nursing. •Physically or mentally incapable or incompetent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Microbiota composition before, during and after 3 cycles systemic treatment with capecitabine or TAS-102 related to respons & chemotoxicity | — |
Secondary
| Measure | Time frame |
|---|---|
| Absolute microbiota abundance before, during and after 3 cycles systemic treatment with capecitabine or TAS-102 related to respons & chemotoxicity | — |
Contacts
Public ContactR Aarnoutse
Maastricht University Medical Center +, Department of Surgery
Outcome results
None listed